INGN-225, an adenoviral vaccine expressing a modified p53 antigen targeting dendritic cells, elicited a specific anti-p53 immune response in 41% of patients with SCLC, highlighting its potential therapeutic relevance given the frequent mutations in the p53 gene [101]. Here, TP53 is linked to small cell lung carcinoma.